{
    "title": "Improving Antibody Humanness Prediction using Patent Data. (arXiv:2401.14442v1 [q-bio.QM])",
    "abstract": "We investigate the potential of patent data for improving the antibody humanness prediction using a multi-stage, multi-loss training process. Humanness serves as a proxy for the immunogenic response to antibody therapeutics, one of the major causes of attrition in drug discovery and a challenging obstacle for their use in clinical settings. We pose the initial learning stage as a weakly-supervised contrastive-learning problem, where each antibody sequence is associated with possibly multiple identifiers of function and the objective is to learn an encoder that groups them according to their patented properties. We then freeze a part of the contrastive encoder and continue training it on the patent data using the cross-entropy loss to predict the humanness score of a given antibody sequence. We illustrate the utility of the patent data and our approach by performing inference on three different immunogenicity datasets, unseen during training. Our empirical results demonstrate that the l",
    "link": "http://arxiv.org/abs/2401.14442",
    "context": "Title: Improving Antibody Humanness Prediction using Patent Data. (arXiv:2401.14442v1 [q-bio.QM])\nAbstract: We investigate the potential of patent data for improving the antibody humanness prediction using a multi-stage, multi-loss training process. Humanness serves as a proxy for the immunogenic response to antibody therapeutics, one of the major causes of attrition in drug discovery and a challenging obstacle for their use in clinical settings. We pose the initial learning stage as a weakly-supervised contrastive-learning problem, where each antibody sequence is associated with possibly multiple identifiers of function and the objective is to learn an encoder that groups them according to their patented properties. We then freeze a part of the contrastive encoder and continue training it on the patent data using the cross-entropy loss to predict the humanness score of a given antibody sequence. We illustrate the utility of the patent data and our approach by performing inference on three different immunogenicity datasets, unseen during training. Our empirical results demonstrate that the l",
    "path": "papers/24/01/2401.14442.json",
    "total_tokens": 873,
    "translated_title": "利用专利数据提高抗体人性预测能力",
    "translated_abstract": "我们研究了利用专利数据来提高抗体人性预测的潜力，采用了多阶段、多损失的训练过程。抗体人性作为对抗体治疗的免疫反应的代理，是药物发现中的主要原因之一，在临床环境中使用抗体治疗面临着具有挑战性的障碍。我们将初始学习阶段视为一个弱监督对比学习问题，每个抗体序列与可能有多个功能标识符相关联，目标是学习一个编码器，根据其专利属性将它们分组。然后，我们冻结对比编码器的一部分，并继续使用交叉熵损失在专利数据上训练，以预测给定抗体序列的人性评分。我们通过对三个不同的免疫原性数据集进行推理，展示了专利数据和我们的方法的效用。我们的实证结果表明，l",
    "tldr": "本研究利用专利数据提高了抗体人性预测的能力，通过多阶段、多损失的训练过程以及弱监督对比学习的方法，成功地预测了抗体序列的人性评分。",
    "en_tdlr": "This study improves antibody humanness prediction by utilizing patent data, achieving successful prediction of humanness scores of antibody sequences through a multi-stage, multi-loss training process and weakly supervised contrastive learning method."
}